Dr. Cai Junjie, VP of AliveX Biotech, Shares AI-Driven Innovations in Tumor Biomarker Discovery at TBM Symposium on Multi-Omics and Artificial Intelligence

January 22,The 25th TBM Online Symposium on "Development of Multi-Omics Big Data and Artificial Intelligence in Oncology" for Industry-Academia-Research CollaborationSuccessfully convened. This meeting was organized byHosted by the Tumor Marker Committee of the China Anti-Cancer AssociationThe conference aims to promote innovation and cooperation in the field of molecular diagnostics for tumors, drive the transformation of scientific research achievements, and deepen the integration of multidisciplinary collaboration.

The conference invited a group of top scholars and industry leaders, including Professor Xing Jinliang from the Air Force Medical University, Professor Zhang Yan from Harbin Institute of Technology, and Dr. Lu Linbin from Mengchao Hepatobiliary Hospital of Fujian Medical University, to jointly discuss the latest applications of big data and artificial intelligence in oncology.Dr. Cai Junjie, Vice President of AliveX Biotech's Computing Platform, was a special guest and shared innovative practices in AI-driven tumor biomarker screening, showcasing the company's core advantages in intelligent analysis.

As a representative of a leading company in the fields of artificial intelligence and bio-computation, Dr. Cai shared the company's innovative practices in tumor marker screening at the conference. He pointed out that medical research often faces the challenge of "small datasets with high-dimensional features," and traditional methods are susceptible to data noise interference, leading to insufficient reliability in marker screening.

AliveX Biotech Computing Platform Addresses This Challenge with Two Major Technological Breakthroughs:

1. Hundred Rounds of Monte Carlo Simulation:Using ultra-large-scale computing power support, consensus features are screened through multiple rounds of simulation, significantly improving the stability of biomarker screening.

2. Fully Automated Analysis Platform:Develop a one-click AI tool to achieve full-process automation from data preprocessing, feature analysis to model validation, lowering the technical threshold and accelerating scientific research transformation.

This computing platform has been successfully applied to multiple cancer research projects, empowering research teams to efficiently explore potential biomarkers, providing scientific evidence for early screening, prognosis evaluation, and targeted therapy.

As the highlight company of this conference,AliveX Biotech leverages its AI-driven computational platform and interdisciplinary team of experts., showcasing its leading capabilities in multi-omics data analysis for cancer research. The company not only provides one-stop solutions from data mining to model validation but also focuses on lowering the barriers to technology application, empowering clinical and research institutions to efficiently advance precision medicine studies.

In the future, AliveX Biotech will continue to deepen its cooperation with academic societies, hospitals, and enterprises, promoting the deep integration of AI technology and cancer research, and contributing innovative strength to the "Healthy China 2030" strategy.

Welcome to follow AliveX Biotech's WeChat Official Account for more cutting-edge technologies and collaboration opportunities in cancer research!